Monday, December 2, 2024
5:30 PM – 6:30 PM: Learning Gallery and Networking Reception
6:30 PM – 7:30 PM: Dinner and CME Presentation
7:30 PM – 8:30 PM: Learning Gallery and Dessert Networking Reception
Le Méridien Philadelphia
1421 Arch Street
Philadelphia, PA, 19102
Meeting Room: Trumbauer Ballroom
Learning Lab Room: Abele Library
PROGRAM FEATURES
-
- Interactive, case-based learning environment
- Downloadable animations
- Create your own personalized poster
PRESENTING FACULTY
 |
Neil M. Bressler, MD The James P. Gills Professor of Ophthalmology Retina Division (Chief: 2005-2018) – Wilmer Eye Institute Johns Hopkins University School of Medicine & Hospital Baltimore, MD Participation by Dr. Neil Bressler in this activity does not constitute or imply endorsement by the Johns Hopkins University, the Johns Hopkins Hospital, the Johns Hopkins Health System, the Jaeb Center for Health Research Foundation, Inc., the FDA, the NIH, the AMA, nor JAMA Ophthalmology |
 |
Susan B. Bressler, MD Professor of Ophthalmology Johns Hopkins University School of Medicine Julia G. Levy, PhD Professor of Ophthalmology, Wilmer Eye Institute Johns Hopkins University School of Medicine Baltimore, MD Participation by Dr. Susan Bressler in this activity does not constitute or imply endorsement by the Johns Hopkins University, the Johns Hopkins Hospital, or the Johns Hopkins Health System. |
PROGRAM OVERVIEW
This interactive live presentation will address the burdens associated with treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) that can contribute to poorer vision outcomes in patients. An extension of the Vision RELIEF: No Eyes Left Behind initiative, intimate group case-study discussions are used to provide retina specialists and comprehensive ophthalmologists with knowledge and tactics to address treatment barriers within anti-VEGF therapy. Using individualized approaches to treatment, such as dosing strategies and use of next-generation anti-VEGF therapy, as well as a panel discussion to enhance the practical integration of addressing treatment burden, you will be equipped with the knowledge and tactics to optimize your patients’ outcomes.
AGENDA
5:30 PM – 6:30 PM: Learning Gallery and Networking Reception
During the networking reception, we will provide attendees with an opportunity to network with our speaking faculty, while they enjoying an Immersive Learning Gallery Experience, that includes many engaging and interactive learning stations with the following components:
- A virtual reality lounge, utilizing Oculus Headsets, with stunning VR 360 animations on optimal patient and physician interactions.
- Interactive Augmented Reality Headsets, where learners can manipulate their virtual environment to learn about DME and nAMD next generation therapies, in an exciting way.
- Create your own clinical practice poster and personalize it with your name and practice.
- View our Vision Relief Website through touchscreens, and get a tour of all of the free tools and resources for clinician and patient education.
- Manage life-sized holographic AI patients Fatima (nAMD) and Lamar (DME), where you can ask them questions and make real-time treatment decisions based on the patient’s responses.
These engaging learning and networking opportunities with top thought leaders are offered before and after the live program to maximize your connections and knowledge to offer your patients the best chance at optimal outcomes.
6:30 PM – 7:30 PM: Dinner and CME Presentation
This interactive live presentation will address the burdens associated with treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) that can contribute to poorer vision outcomes in patients. An extension of the Vision RELIEF: No Eyes Left Behind initiative, intimate group case-study discussions are used to provide retina specialists and comprehensive ophthalmologists with knowledge and tactics to address treatment barriers with anti-VEGF therapy. Using individualized approaches to treatment, such as dosing strategies and use of next-generation anti-VEGF therapy, and a panel discussion to enhance the practical integration of addressing treatment burden, you will be equipped with the knowledge and tactics to optimize your patients’ outcomes.
7:30 PM – 8:30 PM: Learning Gallery and Dessert Networking Reception
Continuation of networking session, opportunity to engage with our expert faculty speakers, and participate in the interactive learning stations listed above.
TARGET AUDIENCE
This initiative is designed to meet the educational needs of retina specialists, comprehensive ophthalmologists, and retina fellows involved in the management of patients with retinal vascular disease.
LEARNING OBJECTIVES
- Evaluate adherence barriers in nAMD and DME treatment, including injection frequency and patient factors
- Analyze the duration of effectiveness in established and emerging therapies for nAMD and DME
- Identify patients eligible for dosing modifications or transitioning to longer-lasting therapies, based on individual, treatment, and disease considerations
- Personalize treatment selection and dosing strategies to optimize care for nAMD and DME patients
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in this live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event Staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to the live event at [email protected]
